fda compounding semaglutide warning september 2025 The has received reports of adverse events after patients used compounded versions of semaglutide. Some compounders may also be using unapproved salt forms. Patients should avoid compounded when an FDA-approved Compound versions of GLP-1 drugs

Eli Lilly FDA Approves Foundayo (April 2026) 13

In that blind spot, experts estimate hundreds of thousands of Americans are taking medicine that hasnt been vetted by the FDA for safety and effectiveness the way a typical prescription drug would be

The Retatrutide Raw Powder should remain in its original sealed packaging until needed, as exposure to ambient moisture and oxygen accelerates degradation processes

Glucagon-like peptide-1 receptor agonists: Drug safety and efficacy in the treatment of type 2 diabetes

Latest Phase 3 Trial Results: TRIUMPH-1 (May 2026) On 21 May 2026, Eli Lilly announced topline results from TRIUMPH-1 , the largest and longest Phase 3 obesity trial conducted for Retatrutide to date

Semaglutide may be an option for adults who struggle with weight loss despite diet and exercise